Related references
Note: Only part of the references are listed.Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Augusto Miravalle et al.
ARCHIVES OF NEUROLOGY (2011)
Observations during an elective interruption of natalizumab treatment: a post-marketing study
Giovanna Borriello et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
P. W. O'Connor et al.
NEUROLOGY (2011)
Natalizumab Drug Holiday in Multiple Sclerosis: Poorly Tolerated
Joep Killestein et al.
ANNALS OF NEUROLOGY (2010)
Considerations on Discontinuing Natalizumab for the Treatment of Multiple Sclerosis
Joseph R. Berger et al.
ANNALS OF NEUROLOGY (2010)
Natalizumab Dosage Suspension: Are We Helping or Hurting?
Timothy W. West et al.
ANNALS OF NEUROLOGY (2010)
Corticosteroids in the treatment of multiple sclerosis
K. M. Myhr et al.
ACTA NEUROLOGICA SCANDINAVICA (2009)
Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis
Richard A. Rudick et al.
LANCET NEUROLOGY (2009)
Is natalizumab overshooting its rebound?
Robert J. Fox et al.
NEUROLOGY (2008)
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
Ludwig Kappos et al.
LANCET NEUROLOGY (2007)
Share Paper
